Luzum, Jasmine A. http://orcid.org/0000-0003-3639-717X
English, Joseph D.
Ahmad, Umair S.
Sun, Jessie W.
Canan, Benjamin D.
Sadee, Wolfgang
Kitzmiller, Joseph P.
Binkley, Philip F.
Funding for this research was provided by:
American Heart Association (14POST20100054)
National Heart, Lung, and Blood Institute (L30 HL110279)
National Center for Advancing Translational Sciences (UL1TR002240)
Article History
Received: 22 October 2018
Accepted: 21 January 2019
First Online: 12 February 2019
Compliance with Ethical Standards
:
: None.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
: No animal studies were carried out by the authors for this article.
: These findings from a small study at a single site need to be replicated in a larger study of multiple sites to be clinically relevant. The potential clinical relevance is that a patient’s <i>ADRB1</i> Ser49Gly (rs1801252) genotype may be a predictor of whether or not the patient with HFrEF will have recovery of their LVEF to ≥ 40%. This genotype was the strongest predictor of LVEF recovery, even compared to multiple clinical variables. Thus, if validated, HFrEF patients that are <i>ADRB1</i> Gly49 carriers may need additional monitoring or therapies compared to Ser49 homozygotes.